These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2645650)

  • 21. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
    Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
    Park HS; Kim DW; Kim CC; Kim HK; Kim JS; Hwang TJ; Kim HJ; Kim HS; Song HS; Park JW; Ahn HS; Chung TJ; Cho KS; Lee KS; Choi YM
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):24-9. PubMed ID: 8916313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The benefit of induction chemotherapy in patients age > or = 75 years.
    Vey N; Coso D; Bardou VJ; Stoppa AM; Braud AC; Bouabdallah R; Sainty D; Mozziconacci MJ; Lafage M; Damaj G; Blaise D; Gastaut JA; Maraninchi D
    Cancer; 2004 Jul; 101(2):325-31. PubMed ID: 15241830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. OAP combination in the treatment of elderly leukaemic patients with preexisting severe internal disease.
    Marra R; Pagano L; Liene DR; Storti S; Girasoli M; Leone G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):187-91. PubMed ID: 2475396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
    Vogler WR; Winton EF; Gordon DS; Raney MR; Go B; Meyer L
    Blood; 1984 May; 63(5):1039-45. PubMed ID: 6201211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Acute myelogenous leukemia in elderly patients].
    Mori M
    Nihon Ronen Igakkai Zasshi; 2000 Mar; 37(3):192-6. PubMed ID: 10879065
    [No Abstract]   [Full Text] [Related]  

  • 27. What is the best induction regimen for acute myelogenous leukemia?
    Rowe JM
    Leukemia; 1998 Sep; 12 Suppl 1():S16-9. PubMed ID: 9777889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acute myeloid leukemia of the elderly: recent progresses in therapy].
    Yamauchi T
    Rinsho Ketsueki; 2018; 59(6):735-740. PubMed ID: 29973453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Advances in treatment of acute myeloid leukemia in the elderly].
    Chen M; Wang SJ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):634-8. PubMed ID: 19968086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Characteristics of elderly patients with acute myelogenous leukemia].
    Wakita A
    Nihon Rinsho; 2009 Oct; 67(10):1997-2002. PubMed ID: 19860204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug treatment of acute myelogenous leukaemia. Current options and future perspectives].
    Telek B; Rejtő L; Batár P; Miltényi Z; Reményi G; Simon Z; Ujj Z; Mezei G; Szász R; Kiss A; Udvardy M; Illés Á
    Orv Hetil; 2016 May; 157(22):843-8. PubMed ID: 27211353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive therapy in elderly patients with acute myeloid leukemia.
    Cassileth PA
    J Clin Oncol; 1990 May; 8(5):937-8. PubMed ID: 2332774
    [No Abstract]   [Full Text] [Related]  

  • 33. [Acute myeloid leukemias in elderly patients].
    Parovichnikova EN; Savchenko VG
    Ter Arkh; 1990; 62(7):148-54. PubMed ID: 2251656
    [No Abstract]   [Full Text] [Related]  

  • 34. Current status of acute myeloid leukemia treatment in the elderly.
    Schiller G
    Clin Adv Hematol Oncol; 2009 Sep; 7(9):580-2. PubMed ID: 20020668
    [No Abstract]   [Full Text] [Related]  

  • 35. Improving the "quality of remission induction" therapy: a necessary step for increasing the cure rate in acute myelogenous leukemia.
    Arlin ZA; Feldman E; Finger L; Decter J; Cook P; Ahmed T; Puccio C; Chun H; Mittelman A
    Cancer Invest; 1992; 10(2):183-4. PubMed ID: 1551027
    [No Abstract]   [Full Text] [Related]  

  • 36. Prediction of induction and duration of complete remission in acute myelogenous leukemia: value of clonogenic cell properties.
    Zittoun R; Marie JP; Brilhante D; Delmer A
    Haematol Blood Transfus; 1987; 30():45-9. PubMed ID: 3476378
    [No Abstract]   [Full Text] [Related]  

  • 37. Infection of elderly patients receiving high dose cytarabine-based chemotherapy for induction treatment of acute myelogenous leukemia (AML).
    Nemunaitis J; Meyer W; Nemunaitis J; Taylor E; Riley C; Cooper B
    Leuk Res; 1994 Aug; 18(8):649-50. PubMed ID: 8065168
    [No Abstract]   [Full Text] [Related]  

  • 38. Evolving treatments in acute myeloid leukemia.
    Roboz GJ
    Clin Adv Hematol Oncol; 2015 Feb; 13(2):93-5. PubMed ID: 25774478
    [No Abstract]   [Full Text] [Related]  

  • 39. Fetal liver infusion in acute myelogenous leukaemia.
    Kochupillai V; Sharma S; Francis S; Nanu A; Verma IC; Dua H; Kumar L; Aggarwal S; Singh S
    Thymus; 1987; 10(1-2):117-24. PubMed ID: 3324400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients.
    Preisler H; Raza A; Larson R; Goldberg J; Tricot G; Carey M; Kukla C
    Leuk Res; 1991; 15(9):773-80. PubMed ID: 1921456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.